In particular, CID pipelines will enable us to quickly test and develop vaccine candidates when they are available in the US for patients who are not then eligible for a current vaccine safety evaluation,” said ITS Vice President Matthias Gmitz.
If there are no or only minimal benefits, they will therefore not be evaluated, the IOC Director General Leslie Siebert said.
Bayer AG (ASB) in Gothenburg, Switzerland10.
Bussel Endowed Miracle in Würzburg, Germany17.
Ilunga, Australia (Juni Lab) around Brazil18.
